New results from the NETTER-1 study that compared Sandostatin LAR 60mg versus treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera have been made available. These findings, released at the 2015 European Cancer Congress, show that for patients living with unresectable mid-gut neuroendocrine cancers that PRRT provided a longer progression free survival than with just long-acting somastatin analogues alone. Read more about the findings of this study.
Previous Post: Petition: Protest the high cost of cancer drugs to patients
Next Post: NET Cancer Day in Minnesota | 2015